Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2021-2026
According to this latest study, the 2021 growth of Glucagon Like Peptide-1 (GLP-1) Agonists will have significant change from previous year. By the most conservative estimates of global Glucagon Like Peptide-1 (GLP-1) Agonists market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 7612.6 million in 2020. Over the next five years the Glucagon Like Peptide-1 (GLP-1) Agonists market will register a 13.8% CAGR in terms of revenue, the global market size will reach US$ 12770 million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon Like Peptide-1 (GLP-1) Agonists market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospital
Pharmacy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption 2016-2026
2.1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Consumption CAGR by Region
2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
2.2.1 Exenatied
2.2.2 Liraglutide
2.2.3 Lixisenatide
2.2.4 Albiglutide
2.2.5 Dulaglutide
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
2.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
2.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Type (2016-2021)
2.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Type (2016-2021)
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
2.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Market Share by Application (2016-2021)
2.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Application (2016-2021)
2.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Application (2016-2021)
3 Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company
3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2019-2021)
3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company (2019-2021)
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company
3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2019-2021)
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2019-2021)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Company
3.4 Global Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Location Distribution
3.4.2 Players Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Glucagon Like Peptide-1 (GLP-1) Agonists by Region
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists by Region
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
4.2 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth
4.3 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth
4.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth
4.5 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth
5 Americas
5.1 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
5.1.1 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
5.1.2 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
5.2 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
5.3 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
6.1.1 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021)
6.1.2 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021)
6.2 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
6.3 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists by Country
7.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
7.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
7.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists by Country
8.1.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
8.1.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
8.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
8.3 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customer
11 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast
11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Region
11.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Regions (2021-2026)
11.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Type
11.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Application
12 Key Players Analysis
12.1 Novo Nordisk
12.1.1 Novo Nordisk Company Information
12.1.2 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Novo Nordisk Main Business Overview
12.1.5 Novo Nordisk Latest Developments
12.2 AstraZeneca
12.2.1 AstraZeneca Company Information
12.2.2 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 AstraZeneca Main Business Overview
12.2.5 AstraZeneca Latest Developments
12.3 Eli Lily
12.3.1 Eli Lily Company Information
12.3.2 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Eli Lily Main Business Overview
12.3.5 Eli Lily Latest Developments
12.4 GSK
12.4.1 GSK Company Information
12.4.2 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 GSK Main Business Overview
12.4.5 GSK Latest Developments
12.5 Sanofi
12.5.1 Sanofi Company Information
12.5.2 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Sanofi Main Business Overview
12.5.5 Sanofi Latest Developments
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Company Information
12.6.2 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Bristol-Myers Squibb Main Business Overview
12.6.5 Bristol-Myers Squibb Latest Developments
12.7 Amylin
12.7.1 Amylin Company Information
12.7.2 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
12.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Amylin Main Business Overview
12.7.5 Amylin Latest Developments
...
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Exenatied
Table 3. Major Players of Liraglutide
Table 4. Major Players of Lixisenatide
Table 5. Major Players of Albiglutide
Table 6. Major Players of Dulaglutide
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) & (K Units)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2016-2021) & ($ million)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Type (2016-2021)
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) & (K Units)
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Value by Application (2016-2021)
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Application (2016-2021)
Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2019-2021) & (K Units)
Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company (2019-2021)
Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2019-2021) ($ Millions)
Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2019-2021)
Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Company (2019-2021)
Table 22. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Producing Area Distribution and Sales Area
Table 23. Players Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
Table 24. Glucagon Like Peptide-1 (GLP-1) Agonists Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021) (K Units)
Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021) & ($ Millions)
Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Table 31. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 32. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 33. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & ($ Millions)
Table 34. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 35. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) & (K Units)
Table 36. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Table 37. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) & (K Units)
Table 38. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Table 39. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021) & (K Units)
Table 40. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Table 41. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021) & ($ Millions)
Table 42. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Table 43. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) & (K Units)
Table 44. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Table 45. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) & (K Units)
Table 46. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Table 47. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 48. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & ($ Millions)
Table 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) & (K Units)
Table 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Table 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) & (K Units)
Table 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Table 55. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 56. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 57. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & ($ Millions)
Table 58. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 59. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) & (K Units)
Table 60. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Table 61. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) & (K Units)
Table 62. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Table 63. Key and Potential Regions of Glucagon Like Peptide-1 (GLP-1) Agonists
Table 64. Key Application and Potential Industries of Glucagon Like Peptide-1 (GLP-1) Agonists
Table 65. Key Challenges of Glucagon Like Peptide-1 (GLP-1) Agonists
Table 66. Key Trends of Glucagon Like Peptide-1 (GLP-1) Agonists
Table 67. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 68. Glucagon Like Peptide-1 (GLP-1) Agonists Customer List
Table 69. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2021-2026) & (K Units)
Table 70. Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Market Forecast by Region
Table 71. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2021-2026) & ($ millions)
Table 72. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Region (2021-2026)
Table 73. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2021-2026) & (K Units)
Table 74. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Country (2021-2026) & ($ millions)
Table 75. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2021-2026) & (K Units)
Table 76. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2021-2026) & ($ millions)
Table 77. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2021-2026) & (K Units)
Table 78. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Country (2021-2026) & ($ millions)
Table 79. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2021-2026) & (K Units)
Table 80. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Country (2021-2026) & ($ millions)
Table 81. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2021-2026) & (K Units)
Table 82. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Type (2021-2026)
Table 83. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 84. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Type (2021-2026)
Table 85. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2021-2026) & (K Units)
Table 86. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Application (2021-2026)
Table 87. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 88. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Application (2021-2026)
Table 89. Novo Nordisk Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 90. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 91. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 92. Novo Nordisk Main Business
Table 93. Novo Nordisk Latest Developments
Table 94. AstraZeneca Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 95. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 96. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 97. AstraZeneca Main Business
Table 98. AstraZeneca Latest Developments
Table 99. Eli Lily Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 100. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 101. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 102. Eli Lily Main Business
Table 103. Eli Lily Latest Developments
Table 104. GSK Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 105. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 106. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 107. GSK Main Business
Table 108. GSK Latest Developments
Table 109. Sanofi Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 110. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 111. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 112. Sanofi Main Business
Table 113. Sanofi Latest Developments
Table 114. Bristol-Myers Squibb Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 115. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 116. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 117. Bristol-Myers Squibb Main Business
Table 118. Bristol-Myers Squibb Latest Developments
Table 119. Amylin Basic Information, Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base, Sales Area and Its Competitors
Table 120. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
Table 121. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 122. Amylin Main Business
Table 123. Amylin Latest Developments
List of Figures
Figure 1. Picture of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure 2. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Exenatied
Figure 10. Product Picture of Liraglutide
Figure 11. Product Picture of Lixisenatide
Figure 12. Product Picture of Albiglutide
Figure 13. Product Picture of Dulaglutide
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
Figure 16. Glucagon Like Peptide-1 (GLP-1) Agonists Consumed in Hospital
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Hospital (2016-2021) & (K Units)
Figure 18. Glucagon Like Peptide-1 (GLP-1) Agonists Consumed in Pharmacy
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Pharmacy (2016-2021) & (K Units)
Figure 20. Glucagon Like Peptide-1 (GLP-1) Agonists Consumed in Other
Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Other (2016-2021) & (K Units)
Figure 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application in 2020
Figure 24. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market by Company in 2020 ($ Million)
Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company in 2020
Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Regions (2016-2021)
Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in 2020
Figure 28. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2021 (K Units)
Figure 29. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2021 ($ Millions)
Figure 30. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2021 (K Units)
Figure 31. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2021 ($ Millions)
Figure 32. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2021 (K Units)
Figure 33. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2021 ($ Millions)
Figure 34. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2021 (K Units)
Figure 35. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2021 ($ Millions)
Figure 36. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 37. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 38. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 39. Americas Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020
Figure 40. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 41. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 42. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 43. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 44. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region in 2020
Figure 45. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Regions in 2020
Figure 46. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 47. APAC Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020
Figure 48. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 49. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 50. Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 51. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 52. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 53. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 55. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 56. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 57. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020
Figure 58. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 59. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 60. UK Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 61. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 62. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 63. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 64. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 65. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 66. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020
Figure 67. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 68. South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 69. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 70. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 71. GCC Country Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth 2016-2021 ($ Millions)
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets